Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Phase 2 Completed 69 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have recurrent or refractory Hodgkin's lymphoma or non-Hodgkin's lymphoma.

Timeline

Start: 1998-04
Primary completion: 2002-11
Completion: 2007-03

Publications

Results Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL, Gross TG, Warkentin P, Vlachos A, Harrison L, Cairo MS. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant. 2011 Feb;17(2):249-58. doi: 10.1016/j.bbmt.2010.07.002. Epub 2010 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	carmustine	Small molecule	300 mg/m2	Intravenous
Subject	carmustine	Small molecule	450 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	—	—
Background	Cyclophosphamide	Other / unclassified	7200 mg/m2	Intravenous
Background	Etoposide	Small molecule	2400 mg/m2	Intravenous

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications